Lexaria Bioscience Corp.
LEXX
$0.60
$0.034.44%
NASDAQ
| 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | |
|---|---|---|---|---|---|
| Revenue | -88.51% | -- | 107.14% | 107.14% | 20.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -88.51% | -- | 107.14% | 107.14% | 20.00% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -88.51% | -- | 107.14% | 107.14% | 20.00% |
| SG&A Expenses | -19.58% | -1.79% | -41.91% | -3.74% | 118.46% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -49.68% | -45.26% | 15.81% | 114.81% | 259.78% |
| Operating Income | 47.22% | 41.52% | -12.33% | -115.18% | -311.83% |
| Income Before Tax | 46.63% | 41.04% | -23.35% | -112.44% | -316.27% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 46.53% | 40.98% | -23.35% | -112.44% | -316.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -26.32% | -13.79% | -22.22% | -42.31% | 18.75% |
| Net Income | 46.56% | 41.01% | -23.39% | -112.67% | -317.74% |
| EBIT | 47.22% | 41.52% | -12.33% | -115.18% | -311.83% |
| EBITDA | 47.87% | 41.42% | -12.20% | -115.27% | -321.52% |
| EPS Basic | 61.72% | 54.01% | 1.01% | -61.04% | -156.88% |
| Normalized Basic EPS | 62.24% | 54.42% | 9.63% | -63.27% | -154.55% |
| EPS Diluted | 61.72% | 54.01% | 1.01% | -61.04% | -156.88% |
| Normalized Diluted EPS | 62.24% | 54.42% | 9.63% | -63.27% | -154.55% |
| Average Basic Shares Outstanding | 39.58% | 28.24% | 24.60% | 32.07% | 62.67% |
| Average Diluted Shares Outstanding | 39.58% | 28.24% | 24.60% | 32.07% | 62.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |